Gantenerumab
Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease.[1][2] A phase I clinical trial has been conducted in 2006/07.[3]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | Beta-amyloid (Aβ40/42) |
Clinical data | |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6496H10072N1740O2024S42 |
Molar mass | 146.3 kg/mol (peptide) g·mol−1 |
![]() ![]() |
Gantenerumab is currently being evaluated in a prodromal Alzheimer's disease population in the Scarlet Road study, a global phase II study of approximately 360 subjects in 100 centers in 15 countries.[4]
One clinical study was stopped on December 19, 2014 after disappointing results.[5]
As of late 2014, Phase III clinical trials are ongoing.[6]
References
- Statement On A Nonproprietary Name Adopted By The Usan Council - Gantenerumab American Medical Association.
- International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
- Clinical trial number NCT00531804 for "A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease" at ClinicalTrials.gov
- http://www.scarletroadstudy.com/en-CA/index.aspx
- http://www.nasdaq.com/press-release/morphosyss-partner-roche-provides-update-on-trial-of-gantenerumab-in-prodromal-alzheimers-patients-20141219-00045
- H. Spreitzer (10 November 2014). "Neue Wirkstoffe – Gantenerumab". Österreichische Apothekerzeitung (in German) (23/2014): 55.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.